On July 9, Qiagen rose 12.83% in regular trading, trading at $42.93/share, with turnover of $289 million.

On the news front, private equity giants EQT, Advent International, and KKR have expressed early-stage acquisition interest in Qiagen, according to reports. The news reignited takeover speculation that first surfaced in January, when Qiagen was reported to be exploring multiple strategic options including a potential sale, which at the time drove the stock up over 10%.

Qiagen is a global leader in sample-to-insight solutions, serving over 500,000 customers in molecular diagnostics and life sciences across more than 100 countries. The involvement of three major buyout firms suggests meaningful competitive tension in any potential bid process, which typically supports valuation expectations. Within the Life Sciences Tools & Services sector, peers showed moderate gains: Thermo Fisher Scientific up 2.32%, Danaher up 2.26%, Illumina up 3.83%, Tempus AI up 6.39%, and Bio-Techne up 0.28%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)